Each patient will receive three to four vials per treatment cycle, totalling between $18,500 to $25,000 per cycle. Packaged with a black box warning of the potential damage ELAHERE can do to ...

The European Commission (EC) has granted marketing authorisation to AbbVie’s Elahere (mirvetuximab soravtansine) for the treatment of folate receptor-alpha (FRα) platinum-resistant ovarian ...

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα ...

AbbVie (ABBV) announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically cleared for folate receptor-alpha (FRα) positive, platinum-resistant ...

AbbVie’s Elahere (mirvetuximab soravtansine-gynx) has demonstrated consistent survival benefits in a subset of ovarian cancer patients, according to results from a confirmatory late-stage trial of the ...

It's important to note that if a patient has a folate receptor alpha expression level that meets the criteria for receiving Elahere [mirvetuximab soravtansine], they are required to have received it.

accused Genmab of stealing confidential information from AbbVie when it acquired ProfoundBio last year in a $1.8 billion deal that gave it rights to a competitor of AbbVie’s cancer drug Elahere.

(RTTNews) - AbbVie (ABBV) announced that final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE or mirvetuximab ...